Showing 751-760 of 821 results for "".
- Viscot Offers New White Ink Markershttps://practicaldermatology.com/news/20140717-viscot_offers_new_white_ink_markers/2459165/Viscot Medical introduced White E•Z Removable Ink™to complement their existing green and red E•Z Removable Ink™ markers. E•Z Removable Ink™ comes off easily with an alcohol swab or water. E•Z Removable Ink™ eliminates the problem of patient
- Changes Afoot at Valeant Pharmaceuticalshttps://practicaldermatology.com/news/changes-afoot-at-valeant-pharmaceuticals/2458527/Amid reports that its Obagi Medical Products and Solta Medical units are on the block, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Valeant CEO Joseph Papa cite
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- The Medical Entrepreneur Symposium Announces Sponsorshttps://practicaldermatology.com/news/20120229-the_medical_entrepreneur_symposium_announces_sponsors/2459863/The Medical Entrepreneur Symposium has finalized agreements with several initial sponsors for its upcoming educational seminar. Citrix GotoMeeting, AdvancedMD, Bernstein Wealth Management, Allergan Cosmetic, Obagi, Merz Aesthetics, and BTL Exilis have all agreed to sponsor the two-and-a-half-day sym
- Allergan Reports Positive Topline Results From Studies of TrenibotulinumtoxinE for Glabellar Lineshttps://practicaldermatology.com/news/allergan-reports-positive-topline-results-from-studies-of-trenibotulinumtoxine-for-glabellar-lines/2462093/Allergan Aesthetics’ trenibotulinumtoxinE (BoNT/E) performed well for the treatment of moderate to severe glabellar lines, according to topline results from two pivotal Phase 3 studies. BoNT/E is a novel botulinum neurotoxin serotype E with a quick onset of action
- Bonti Takes Aim at Scar Reduction with Shine Clinical Programhttps://practicaldermatology.com/news/bonti-takes-aim-at-scar-reduction-with-shine-clinical-program/2457897/Bonti has begun their SHINE (Scar Healing Improvement with Neurotoxin E) clinical program, aimed at scar reduction using its novel neurotoxin. EB- 001 is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique product profile, characterized
- Cutera Unveils Free Digital Resources to Help Practices Thrive Through COVID-19 and Beyondhttps://practicaldermatology.com/news/cutera-unveils-new-free-digital-resources-to-help-practices-thrive-through-covid-19-and-beyond/2460366/CUTERA, INC. is launching the Cutera University e-learning series to support medical professionals through the COVID-19 crisis and beyond. The Cutera University e-learning series offers compli
- Bonti's Novel Neurotoxin Shines in Early Study of Scar Reduction After Mohs Surgeryhttps://practicaldermatology.com/news/bontis-novel-neurotoxin-shines-in-early-study-of-scar-reduction-after-mohs-surgery/2457662/Topline results from Bonti’s SHINE-1 Phase 2a clinical trial suggest that its novel neurotoxin is safe and likely effective for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical
- Alcohol May Influence Skin Cancer Riskhttps://practicaldermatology.com/news/20120720-alcohol_may_influence_skin_cancer_risk/2459766/Evidence suggests that alcohol consumption may have some influence on risk for developing BCC but not SCC. (J Invest Dermatol. E-pub) Consumption of wine and spirits, specifically, appears to increase BCC risk, while beer consumption does not. Results come from an analysis of data on 54,766 people e
- Almirall, Sun Pharma Enter into a License Agreement for Psoriasis Drug Tildrakizumab in Europehttps://practicaldermatology.com/news/almirall-sun-pharma-enter-into-a-license-agreement-for-psoriasis-drug-tildrakizumab-in-europe/2458485/Sun Pharmaceutical Industries Ltd and Almirall will work together to develop and commercialize tildrakizumab for psoriasis in Europe. Tildrakizumab is an investigational IL-23p19 inhibitor currently being e